Insulet Omnipod 5 produces positive study outcomes in type 2 population
February 14, 2025
JAMA today published outcomes from a study evaluating the safety and efficacy of the Insulet Omnipod 5 in adults with type 2 diabetes.
JAMA today published outcomes from a study evaluating the safety and efficacy of the Insulet Omnipod 5 in adults with type 2 diabetes.
An enzyme called cyclin-dependent kinase 2 (CDK2) regulates the cell cycle and may have the potential to drive therapeutic resistance to common breast cancer drugs—including a class of targeted treatments known as CDK4/6 inhibitors. A new study led by Agnieszka Witkiewicz, MD, and Erik Knudsen, Ph.D., of Roswell Park Comprehensive Cancer Center and colleagues highlights the therapeutic impact of CDK2 inhibitors and is published in the journal Nature Communications.
The U.S. Senate voted 52–48 today to confirm Robert F. Kennedy Jr. as the new secretary of the U.S. Department of Health and Human Services.
BOSTON, Feb. 11, 2025 /PRNewswire/ — InnoVoyce, a leading medical technology company, proudly announces its ISO 13485:2016 certification, underscoring its dedication to excellence in the design, manufacturing, installation, and servicing of lasers and fiber devices. Alongside this milestone, the company is thrilled to share that its FDA-cleared VYLO™ 455nm Blue Light Laser System is now available nationwide, offering healthcare professionals an advanced tool for treating laryngeal disorders and a wide range of surgical applications.
CHICAGO, Feb. 6, 2025 /PRNewswire/ — Sibel Health, an award-winning medical technology company that develops advanced wearable sensors, software, and AI/ML algorithms for clinical trials and clinical care, is pleased to announce a major peer-reviewed publication, “Artificial Intelligence-Enabled Wearable Devices and Nocturnal Scratching in Mild Atopic Dermatitis,” in JAMA Dermatology. This research describes a groundbreaking digital health technology designed to measure and reduce nighttime scratching in people with mild atopic dermatitis.
Stereotaxis (NYSE:STXS) said today that it has secured CE mark approval for its Magic robotically-navigated magnetic ablation catheter.
GT Medical Technologies announced today that it completed a $37 million first close of a Series D financing round.
Medtronic (NYSE: MDT)+
announced that CMS is opening a national coverage analysis on renal denervation (RDN) procedures for patients with hypertension.
Robeauté announced today that it raised $28 million to support the development of its neurosurgical microrobot technology.
ENGLEWOOD CLIFFS, N.J., Jan. 13, 2025 /PRNewswire/ — BRAIN.Q, is excited to announce the CE Mark for its BQ 2.0 system, designed to reduce disability following ischemic stroke, the number one cause of disability worldwide.